文献速递急性肾损伤

危重患儿尿NGAL预测2/3期急性肾损伤的截断值推导与验证

Derivation and Validation of an Optimal Neutrophil Gelatinase-Associated Lipocalin Cutoff to Predict Stage 2/3 Acute Kidney Injury (AKI) in Critically Ill Children.
PubMed 文献 · Kidney Int Rep · 2024-05-15

这项前瞻性多中心研究在危重患儿中推导并验证了尿中性粒细胞明胶酶相关脂质运载蛋白(uNGAL)预测48-72小时2/3期急性肾损伤(AKI)的最佳截断值。推导队列确定125 ng/ml为最佳截断值,验证队列中uNGAL的AUC-ROC为0.83,敏感度72.3%、特异度86.3%、阴性预测值96.9%。结果表明入院24小时内uNGAL能很好地预测KDIGO 2/3期AKI。

要点

  • uNGAL 125 ng/ml是预测危重患儿48-72小时2/3期AKI的最佳截断值。
  • 验证队列中uNGAL预测2/3期AKI的AUC-ROC为0.83,阴性预测值高达96.9%。
  • 入院24小时内检测uNGAL有助于危重患儿2/3期AKI的风险评估。

核心结论

  • 危重患儿入院24小时内uNGAL能很好地预测48-72小时KDIGO 2/3期AKI。
  • uNGAL截断值125 ng/ml可辅助评估2/3期AKI的持续或发生风险。

研究设计与样本

  • 前瞻性多中心研究,纳入年龄≥90天至<22岁、入住ICU且满足机械通气、血管活性药物、实体器官或骨髓移植、或入院24小时内低血压之一条件的患儿。
  • uNGAL在入院24小时内检测,主要结局为48-72小时基于血肌酐的2/3期AKI。

主要发现

  • uNGAL预测2/3期AKI的最佳截断值为125 ng/ml。
  • 验证队列中uNGAL的AUC-ROC为0.83(95%CI:0.77-0.90)。
  • 敏感度72.3%(95%CI:57.4%-84.4%),特异度86.3%(95%CI:82.8%-89.3%)。
  • 阳性预测值34.7%(95%CI:28.5%-41.5%),阴性预测值96.9%(95%CI:95.1%-98.0%)。

关键数值与推荐

  • uNGAL截断值125 ng/ml用于预测危重患儿48-72小时2/3期AKI。
  • 验证队列AUC-ROC 0.83(95%CI:0.77-0.90),阴性预测值96.9%(95%CI:95.1%-98.0%)。

临床怎么用

  • 对符合纳入标准的危重患儿,入院24小时内检测uNGAL,以125 ng/ml为截断值辅助评估48-72小时2/3期AKI风险。
  • uNGAL阴性预测值高,可用于识别2/3期AKI低风险患儿。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute kidney injury (AKI) defined by changes in serum creatinine (SCr), or oliguria is associated with increased morbidity and mortality in children who are critically ill. We derived and validated a clinical cutoff value for urine neutrophil gelatinase-associated lipocalin (NGAL), in a prospective multicenter study of children who were critically ill. We report the clinical performance of urine NGAL (uNGAL) to aid in pediatric AKI risk assessment. METHODS: Eligible subjects were aged ≥ 90 days to < 22 years, admitted to an intensive care unit (ICU), and had 1 or more of the following: mechanical ventilation, vasoactive medication administration, solid organ or bone marrow transplantation, or hypotension within 24-hours of admission. uNGAL was assessed within 24-hours of admission. The primary outcome was SCr-based stage 2/3 AKI presence at 48- to 72-hours. RESULTS: Twenty-five (12.3%) derivation study patients had stage 2/3 AKI at 48- to 72-hours. uNGAL concentration of 125 ng/ml was the optimal cutoff. Forty-seven (9.1%) validation study patients had stage 2/3 AKI at 48- to 72-hours. The area under the curve of a receiver operator characteristics curve (AUC-ROC) for uNGAL performance was 0.83 (95% confidence interval [CI]: 0.77-0.90). Performance characteristics were sensitivity 72.3% (95% CI: 57.4%-84.4%), specificity 86.3% (95% CI: 82.8%-89.3%), positive predictive value 34.7% (95% CI: 28.5%-41.5%), and negative predictive value 96.9% (95% CI: 95.1%-98.0%). CONCLUSION: These prospective, pediatric, multicenter studies demonstrate that uNGAL in the first 24-hours performs very well to predict Kidney Disease Improving Global Outcomes (KDIGO) stage 2/3 AKI at 48- to 72-hours into an ICU course. We suggest that a uNGAL cut point of 125 ng/ml can aid in the risk assessment for stage 2/3 AKI persistence or development.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Goldstein SL, Akcan-Arikan A, Afonso N, et al. Derivation and Validation of an Optimal Neutrophil Gelatinase-Associated Lipocalin Cutoff to Predict Stage 2/3 Acute Kidney Injury (AKI) in Critically Ill Children. Kidney Int Rep. 2024. PMID: 39156146. doi:10.1016/j.ekir.2024.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。